Bradycardia Induced by Irinotecan: A Case Report

Japanese Journal of Clinical Oncology

Volumn 28, Issue 11, 1998, Pages 709-711

  Miya, Toshimichi ^a   Fujikawa, Rina ^a   Fukushima, Jun Ichi ^a   Nogami, Hiroshi ^a   Koshiishi, Yoshihiko ^a   Goya, Tomoyuki ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Cardiovascular toxicity; Cholinergic effect; Limited sampling model

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; IRINOTECAN;

AGED; ARTICLE; BRADYCARDIA; CASE REPORT; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DIARRHEA; ELECTROCARDIOGRAPHY; HUMAN; MALE; METABOLISM;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRADYCARDIA; CAMPTOTHECIN; CHOLINERGIC AGENTS; COLONIC NEOPLASMS; DIARRHEA; ELECTROCARDIOGRAPHY; HUMANS; MALE;

EID: 0032215209     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.11.709     Document Type: Article

References (15)

1. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidmo)-1-piperidino]carbonyloxcamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7.
2. Tsuji T, Kanada N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio-Dyn 1991;14:341-9.
3. Kawato Y, Aonuma M, Hirota T, Kuga H, Sato K. Intracellular role of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
4. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, et al. Phase I study of weekly intravenous infusion of CPT-11, anew derivative of camptothecin in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991;83:1164-8.
5. Takeuchi S, Takamizawa H, Takada Y, Okawa T, Tamaya Y. Noda K. et al. Late phase II study of CPT-11, camptothecin derivative, in advanced cervical carcinoma Proc Am Soc Clin Oncol 1992;11:224.
6. Shimada Y, Yoshino M, Wakui A, Nagao I, Futatsugi K, Sakata Y. et al. Phase II study of CPT-11. a new camptothecin derivative, in metastatic colorectal cancer J Clin Oncol 1993;11:909-3
7. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990;8:1907-12.
8. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K. et al. Toxicity grading criteria of Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
9. Sasaki Y, Mizuno S, Fujii H, Ohtsu T, Wakita H, Igarashi T, et al. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 1995;86:117-23.
10. Sasaki Y, Toshida Y, Sudoh K, Hakusui H, Fujii H. Ohtsu T. et al. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995;86:111-6.
11. Yokoi T, Narita M, Nagai E, Hagiwara H, Aburada M, Kamataki T. Inhibition of UDP-glucuronosyl transferase by aglycons of natural glucuronides in Kampo medicines using SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Jpn J Cancer Res 1995;86:985-9
12. Ikuno N. Soda H, Watanabe M, Oka M. Innotecan (CPT-11) and characteristic mucosal change in the mouse ileum and cecum. J Natl Cancer Inst 1995;87:1876-83.
13. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients J Clin Oncol 1995;13:210-21
14. Abigerges D, Armand JP, Chabot GG, Costa LD, Fadel E, Cote C, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-9.
15. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P. et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251-60.